The U.S. FDA denied Lexicon Pharmaceuticals Inc.’s appeal against the rejection of the add-on treatment Zynquista for type 1 diabetes, marking the company’s third major setback during 2019.
Lexicon Pharmaceuticals Inc. said France’s Sanofi SA will pay the Texas-based drugmaker $260 million for the termination of their partnership to develop the diabetes drug Zynquista.
Amgen And Merck Announce Cancer Immunotherapy Collaboration For Patients With Non-Hodgkin Lymphoma
Anti-colony-stimulating factor 1 receptor (CSF1R) antibodies, B Cell Lymphomas, Beta Blockers, Biology, Biotech, Bispecific CD19-directed CD3 T cell engager (BiTE) antibodies, Business, Clinical Trials, Collaboration, Collaborations, Colorectal Cancer, Diabetes, Diabetic Ketoacidosis, Diffuse large B-cell lymphoma (DLBCL), Health, Hyperthyroidism, Hypophysitis, Immune System, Immune Systems, Immunotherapies, Immunotherapy, Lymphomas, Monoclonal Antibodies, Monoclonal Antibodies, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Oncology, Pneumonitis, R&D, Studies, Therapeutics, Tumors, Type 1 DiabetesTHOUSAND OAKS, Calif. and KENILWORTH, N.J., Dec. 4, 2015 /PRNewswire/ — Amgen (NASDAQ: AMGN) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced a cancer immunotherapy collaboration to support a Phase 1b/3 study investigating BLINCYTO® (blinatumomab) in combination with KEYTRUDA® (pembrolizumab) in patients with diffuse large B-cell lymphoma (DLBCL), which […]
